降糖类药物GLP-1受体激动剂与DPP-4抑制剂的药物经济学、血糖指标、药物不良反应情况对比

Comparison of Hypoglycemic Drugs GLP-1 Receptor Agonists and DPP-4 Inhibitors in Pharmacoeconomics,Blood Glucose Indicators,and Adverse Drug Reactions

目的 对比分析降糖类药物胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂、二肽基肽酶-4(dipeptidyl peptidases,DPP-4)抑制剂对2型糖尿病的药物经济学、血糖指标、药物不良反应情况。方法选取2021年1月—2022年1月湖南省职业病防治院78例2型糖尿病患者展开临床研究,实施随机抽签法分为两组,各39例。对照组应用DPP-4抑制剂治疗,观察组应用GLP-1受体激动剂治疗。患者持续用药18周,比较两组患者的血浆空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、不良反应发生率、治疗总费用。结果 治疗18周后,观察组FPG、HbA1c、2 hPG、TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率7.69%与对照组10.26%比较,差异无统计学意义(P>0.05)。观察组治疗18周花费的药物费用比对照组多2 682元。结论 降糖类药物GLP-1受体激动剂可有效治疗2型糖尿病,对血糖指标控制效果较好,但用药费用较高,临床可结合患者实际情况给药。

Objective To compare and analyze the effects of hypoglycemic drugs GLP-1 receptor agonists and DPP-4 inhibitors on the pharmacoeconomics,blood glucose indexes and adverse drug reactions of type 2 diabetes.Methods A total of 78 patients with type 2 diabetes in Hunan Occupational Disease Prevention and Control Hospital from January 2021 to January 2022 were selected for clinical study.The random lottery method was divided into two groups,with 39 cases in each group.The control group treated with DPP-4 inhibitor,and the observation group treated with GLP-1 receptor agonist.The patients continued to take medication for 18 weeks,and the plasma fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c),postprandial 2 h blood glucose(2 hPG),triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),incidence of adverse reactions,total treatment cost were compared.Results After 18 weeks of treatment,the levels of FPG,HbA1c,2 hPG,TG,TC and LDL-C in the observation group were lower than those in the control group,the level of HDL-C in the observation group was higher than that in the control group,the difference was statistically significant(P0.05).The drug cost of the observation group for 18 weeks was 2 682 yuan more than that of the control group.Conclusion Hypoglycemic drugs and GLP-1 receptor agonists can effectively treat type 2 diabetes and have a good effect on the control of blood glucose indicators,but the cost of medication is high,and can be administered clinically in combination with the actual situation of patients.